188 related articles for article (PubMed ID: 35246967)
1. Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation.
Pietilä-Effati P; Söderström J; Saarinen JT; Löyttyniemi E; Kantola I
Mol Genet Genomic Med; 2022 May; 10(5):e1915. PubMed ID: 35246967
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study.
Pietilä-Effati P; Saarinen JT; Löyttyniemi E; Saarenhovi M; Autio R; Kantola I
Am J Med Genet A; 2023 Jul; 191(7):1858-1869. PubMed ID: 37078610
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
4. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
5. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
F1000Res; 2021; 10():841. PubMed ID: 34745562
[TBL] [Abstract][Full Text] [Related]
6. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.
Suntjens EB; Smid BE; Biegstraaten M; Dreschler WA; Hollak CE; Linthorst GE
J Inherit Metab Dis; 2015 Mar; 38(2):351-8. PubMed ID: 25395255
[TBL] [Abstract][Full Text] [Related]
7. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
[TBL] [Abstract][Full Text] [Related]
8. The heart in Fabry's disease.
Sheppard MN
Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis.
Muto R; Suzuki Y; Shimizu H; Yasuda K; Ishimoto T; Maruyama S; Ito Y; Mizuno M
Intern Med; 2023 Feb; 62(4):565-569. PubMed ID: 35831104
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
[TBL] [Abstract][Full Text] [Related]
12. Precision medicine in Fabry disease.
Lenders M; Brand E
Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
[TBL] [Abstract][Full Text] [Related]
14. CD77 levels over enzyme replacement treatment in Fabry Disease Family (V269M).
Pereira EM; Silva ASD; Silva RND; Monte Neto JT; Nascimento FFD; Sousa JLM; Costa Filho HCSAL; Sales Filho HLA; Labilloy A; Monte SJHD
J Bras Nefrol; 2018; 40(4):333-338. PubMed ID: 29927462
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease: Review and experience during newborn screening.
Hsu TR; Niu DM
Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
17. Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.
Pereira EM; do Monte SJ; do Nascimento FF; de Castro JA; Sousa JL; Filho HC; da Silva RN; Labilloy A; Monte Neto JT; da Silva AS
Gene; 2014 Feb; 536(1):118-22. PubMed ID: 24334114
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease.
Thomas AS; Hughes DA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():88-101. PubMed ID: 25345090
[TBL] [Abstract][Full Text] [Related]
19. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
20. Natural course of Fabry disease with the p. Arg227Ter (p.R227*) mutation in Finland: Fast study.
Pietilä-Effati P; Saarinen JT; Löyttyniemi E; Autio R; Saarenhovi M; Haanpää MK; Kantola I
Mol Genet Genomic Med; 2019 Oct; 7(10):e00930. PubMed ID: 31411008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]